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Abstract
Despite high pre-exposure prophylaxis (PrEP) acceptability among people who inject drugs 
(PWID) and PrEP providers, PrEP uptake is low and little is known about how to promote PrEP 
among PWID. This qualitative study with providers in North Carolina explored views on PrEP 
delivery approaches for PWID. Interviewers conducted semistructured interviews with 10 PrEP 
providers and 10 harm reduction (HR) providers. Interviews were transcribed and analyzed. Many 
participants expressed acceptability for providing PrEP referrals at syringe exchange sites, 
stationing PrEP providers at syringe exchange sites to provide PrEP prescriptions, and providing 
standing orders for PrEP at syringe exchange sites. Barriers were identified, including low PrEP 
awareness and limited resources. Many advocated for co-location of HR and PrEP services and 
scaled-up outreach services. PrEP providers emphasized maintenance of clinical requirements, 
while HR providers emphasized flexibility when treating PWID. Promoting PrEP uptake and 
adherence among PWID likely requires integration of HR and PrEP services.
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Pre-exposure prophylaxis (PrEP) is a once-daily oral HIV prevention medication 
(emtricitabine/tenofovir, also called FTC/TDF). A randomized controlled trial in Bangkok, 
Thailand found that PrEP substantially reduces the risk of HIV infection among people who 
inject drugs (PWID), demonstrating that PrEP should be considered part of a HIV 
prevention package for PWID (Choopanya et al., 2013). Additionally, research has shown 
high PrEP acceptability among PWID and medical providers who prescribe PrEP (Edelman 
et al., 2017; Kuo et al., 2016; Martin et al., 2017). However, PrEP uptake is low and little is 
known about how to design and implement interventions that effectively increase PrEP 
uptake and adherence among PWID (Escudero, Lurie, Kerr, Howe, & Marshall, 2014; Roth, 
et al., 2018, 2019.
The opioid epidemic has had a large impact on North Carolina (NC) (Rudd, Seth, David, & 
Scholl, 2016), underscoring the need for HIV prevention services for PWID in that state. In 
NC, the rate of HIV is four times higher than the national average, and over 10% of all HIV 
infection cases are attributable to injection drug use (IDU) (North Carolina HIV/STD/
Hepatitis Surveillance Unit, 2016). Heroin-related overdose deaths have also risen 565% 
over the past 4 years, and hepatitis C virus (HCV) cases have more than doubled, pointing to 
increased rates of IDU in recent years in NC (Rudd et al., 2016). In response, in July 2016, 
NC legalized syringe exchange—the only state in the Southern U.S. to do so. As of March 
2017, over 16 syringe exchange programs staffed with harm reduction providers had been 
established across NC. Harm reduction programs, such as syringe exchange, aim to reduce 
negative health, social, and legal effects associated with drug use while respecting the rights 
of PWID and creating a stigma-free environment (Harm Reduction International, n.d.). 
Syringe exchange programs can offer a bridge to other needed services (Strathdee et al., 
1999) and may be an opportunity to deliver PrEP or link PWID to local PrEP clinics. 
Research is urgently needed to understand how to package PrEP as a harm reduction tool 
that might be efficacious and/or make PWID more likely to engage in other harm reduction 
techniques. As PrEP requires a doctor’s prescription, it is critical to understand both PrEP 
and harm reduction providers’ perspectives on PrEP delivery in harm reduction settings for 
PWID.
This article presents findings from a qualitative study with PrEP and harm reduction 
providers conducted in the Triad and Triangle region of NC that explored (1) experiences 
prescribing or referring PWID to PrEP, (2) perceived acceptability and benefits of providing 
PrEP to PWID, (3) perceived barriers and facilitators to PrEP uptake, adherence, and 
retention for PWID, and (4) views on PrEP delivery to PWID including gauging the 
feasibility and acceptability of packaging PrEP as a harm reduction tool.
Hershow et al. Page 2















The study took place in NC’s Triad and Triangle region, which consists of 20 rural, medium 
metropolitan, and large metropolitan counties. The Triad and Triangle region is located 
across north-central NC with a total estimated population of over 3.5 million people. Most of 
the counties in the Triad and Triangle region have higher HIV incidence rates than other 
counties in NC, with a range of 3-year average county rates for newly diagnosed HIV cases 
of 5.6–27.4 per 100,000 population (North Carolina HIV/STD/Hepatitis Surveillance Unit, 
2017).
STUDY RECRUITMENT
Individuals who provided PrEP (MDs, mid-level providers, registered nurses) and harm 
reduction outreach workers were recruited to provide institutional-level perspectives on 
PrEP. The authors utilized the NC AIDS Training Center’s up-to-date list of PrEP providers 
to locate clinicians in the Triad and Triangle area (see https://www.med.unc.edu/
ncaidstraining/clincian-resources/prep/prep-for-consumers/). Similarly, harm reduction 
outreach workers were identified from the North Carolina Harm Reduction Coalition’s 
website (www.nchrc.org). With both groups of providers, we then utilized snowball 
sampling procedures by asking sampled participants to name other individuals who are PrEP 
or harm reduction providers. The study objectives and procedures were introduced by email 
and other forms of direct outreach to PrEP and harm reduction providers. Introductory 
recruitment materials included instructions on how to contact researchers for eligibility 
screening and, if found eligible, how to schedule an interview.
DATA COLLECTION
From January to April 2018, a trained research assistant conducted 20 semistructured 
interviews with PrEP clinicians (n = 10) and harm reduction providers (n = 10). Prior to data 
collection, verbal informed consent was obtained from each participant. We did not collect 
demographic data to ensure that the participants could not be identified. Interviews assessed 
experiences prescribing or referring PWID to PrEP, perceived benefits of providing PrEP to 
PWID, acceptability of PrEP for PWID, possible barriers and facilitators to PrEP 
implementation for PWID, and ideas related to packaging of PrEP as a harm reduction tool 
that could be deployed in combination with syringe exchange and other PrEP provision 
preferences (see Table 1). In particular, providers were asked to discuss the strengths, 
weaknesses, and any suggestions for improvement for three PrEP provision modalities for 
PWID: (1) syringe exchange sites providing PrEP referrals to interested PWID, (2) 
stationing a PrEP provider at a syringe exchange who provides PrEP prescriptions to 
interested PWID, and (3) syringe exchange sites providing a standing order for PrEP (i.e., 
30-day pill pack) to interested PWID. They were also asked for other suggested modalities 
for PrEP provision to PWID. There were a few questions in the guide that were not 
systematically asked to all participants due to interview flow and time constraints; these 
instances are noted when presenting the results. Interviews lasted approximately 60 minutes 
and were conducted at the provider’s workplace (e.g., PrEP clinic) or over the phone, based 
on the provider’s availability and preference. All participants were given a $10 Starbucks 
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gift card for participation. Interviews were audio recorded and transcribed by an external 
transcription company for analysis.
DATA ANALYSIS
We utilized a general inductive approach (Thomas, 2006), which allows for qualitative data 
to be segmented into codes that align with the research objectives and questions asked of 
participants. One investigator and one research assistant reviewed four (20%) of the 
transcribed interviews to develop the codebook. The codebook mostly included topical 
codes derived from the interview guide, although a few interpretive codes were added based 
on patterns identified in the data. For example, since many participants described provider 
stigma towards PWID in health care settings, a “Provider stigma” code was created. 
Transcripts were coded using NVivo11 software. Initially, the investigator and research 
assistant co-coded seven of the transcripts (n = 3 PrEP providers; n = 4 harm reduction 
providers) to ensure intercoder agreement. For these seven transcripts, they independently 
coded each transcript and then compared coding decisions. If there were disagreements on 
how to use a code, the investigator and research assistant discussed the issue and agreed on a 
revision to the codebook to avoid similar disagreements in the future. Once the codebook 
was finalized, the research assistant independently coded the remaining 13 transcripts.
After coding was completed, code summaries were written by the research assistant. Code 
summaries were created by reviewing all excerpts applied to each code and documenting 
any patterns or differences in responses across participants. Each code summary was split 
between PrEP and harm reduction providers to facilitate comparisons between these two 
groups of providers. By reviewing the code summaries, similarities and differences within 
each provider group and between PrEP and harm reduction providers were identified.
ETHICS
The study was approved by the ethical review committee at the University of North 
Carolina-Chapel Hill.
RESULTS
EXPERIENCES PRESCRIBING OR REFERRING PWID TO PREP
PrEP Providers.—All PrEP providers were asked about their experiences prescribing 
PrEP to PWID in NC, and only one said he had ever prescribed PrEP to a patient who injects 
drugs. This provider noted that he was unsure whether he had ever followed up with the 
patient after initially prescribing it. Some of the remaining providers who had never 
prescribed PrEP to PWID explained that none of their patients had disclosed IDU and that 
their patients were prescribed PrEP due to risky sexual behavior, noting that most of their 
PrEP patients are men who have sex with men (MSM).
Most of the PrEP providers were also asked about the nature and strength of their 
relationships with harm reduction providers. A little over half noted that they had no formal 
relationships with harm reduction providers, although they or social workers in their 
department often referred substance-using patients to harm reduction organizations. These 
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providers thought it would be beneficial for their patients to formally build relationships 
with harm reduction providers. They recognized that harm reduction organizations provide 
clean needles and a nonjudgmental and nonstigmatizing environment for PWID and 
therefore are uniquely positioned to work with PWID. However, a few of these providers 
noted serious challenges to formalizing relationships with harm reduction organizations, 
including lack of time and resources. Some also noted that potential negative press due to 
political views on syringe exchange could be an issue they face when formalizing 
relationships. One provider explained that there were challenges on both sides of the referral 
relationship. This provider noted that harm reduction providers face difficulties identifying 
PrEP service delivery sites for referral due to low availability or awareness. She also 
explained that syringe exchange sites are understaffed and underfunded, making it difficult 
to focus their efforts on providing high-quality PrEP education to PWID, which would help 
drive referrals.
Harm Reduction Providers.—All harm reduction providers were asked whether they 
were aware of any PWID taking PrEP. Only one harm reduction provider knew a client who 
injects drugs who was taking PrEP, explaining that the individual was taking PrEP because 
his/her sexual partner is HIV infected. The remaining providers gave multiple potential 
reasons that their clients who inject drugs were not on PrEP, such as lack of engagement in 
health care, PrEP-related cost barriers, HIV-related stigma, and/or low PrEP awareness. 
Similar to PrEP providers, a couple of harm reduction providers noted that they were mostly 
aware of members of the LGBTQ population accessing PrEP, not PWID.
All harm reduction providers were also asked about their experiences referring PWID to 
PrEP services. Despite limited awareness of PWID taking PrEP, a little over half said that 
they were actively referring PWID to PrEP providers, although the strength and structure of 
the referral system varied. Some had more formal relationships with particular clinics or 
hospitals. One provider explained that “warm handoffs” (Harm reduction provider) were 
provided, meaning the harm reduction providers physically accompanied their clients who 
inject drugs to care; another explained that the syringe exchange he worked at was located in 
the same building as a PrEP provider, allowing him to easily coordinate referrals with the 
clinic in person. Other providers explained that there were few PrEP providers to choose 
from, so they referred any interested PWID to the only available PrEP services in the area, 
without a formal collaboration in place.
The remaining harm reduction providers were not actively referring PWID to PrEP services, 
either because they had not yet identified PrEP providers for referral or they had previously 
tried to refer clients and found that clients faced issues accessing services. One provider who 
was trying to identify and build relationships with PrEP providers emphasized the 
importance of collaboration between syringe exchange and PrEP providers to successfully 
promote PrEP among PWID:
I’d just like to add like we’re ready and willing. So you just gotta find us some 
PrEP providers [chuckles] and you gotta find some that are willing to partner with 
us, and not just lead the crusade on their own, ‘cause I don’t think it would be as 
successful without really combining that harm reduction piece that’s gonna be so 
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key to reaching out to those populations. Like, it’s the reason why some folks have 
not been to a doctor to have this conversation and will be the first time hearing it at 
a syringe exchange.
(Harm reduction provider)
A few harm reduction providers stipulated that in order to feel comfortable referring PWID 
to a PrEP provider it was critical to identify PrEP providers who would be nonjudgmental 
and nonstigmatizing towards PWID.
Perceived Benefits and Advantages of Providing PrEP to PWID.—All harm 
reduction and PrEP providers agreed that PrEP would be beneficial for PWID because many 
PWID are at high risk of getting HIV. Some providers added that many PWID are not only 
at risk for HIV from injection drug use but also from engaging in condom-less sex and other 
risky sexual behaviors.
All who were asked felt that offering PrEP to PWID would increase PWID’s access to other 
harm reduction services. One PrEP provider noted, “I would also say that PrEP is a carrot to 
get a patient engaged in regular health care, and that, then, is an opportunity pretty much 
every time you see the patient to talk about risk reduction, medically assisted therapy.” Many 
providers noted that PWID who are interested in PrEP are more likely to be interested in 
engaging with other health services that offer health-related protection.
While most providers agreed that PrEP would be beneficial for PWID, a few harm reduction 
and PrEP providers also expressed concerns around risk compensation, mentioning that 
using PrEP may lead to increased HIV/STI risk behavior among PWID. These providers 
explained that PWID taking PrEP may get a “false sense of protection” (PrEP provider) and 
exercise increased risk behavior.
PREP ACCEPTABILITY AMONG PWID
Among the harm reduction and PrEP providers who were asked about PrEP acceptability, 
many agreed that PWID would generally be interested in taking PrEP. A few harm reduction 
providers even noted that they had directly talked to PWID about PrEP, and during these 
conversations the clients had shown interest. Despite agreement that PWID would find PrEP 
acceptable, almost all of these providers also noted significant barriers to PrEP uptake, 
including low PrEP awareness, stigma, and drug addiction.
PrEP Awareness Among PWID.—Harm reduction and PrEP providers commonly 
mentioned that PWID are often unaware of PrEP and pointed to the need for PWID-targeted 
PrEP education campaigns to promote PrEP acceptability. One provider explained why 
PWID may not respond to LGBTQ-targeted PrEP campaigns, speaking specifically about a 
PrEP poster at a syringe exchange site that featured two men hugging: “So, if I was a 
heterosexual man or woman, especially a woman, and I saw that poster, I wouldn’t think I 
would be included in that conversation…” (Harm reduction provider). When asked about the 
optimal ways to increase PrEP awareness among PWID, some harm reduction and PrEP 
providers noted that it would be important to deliver PrEP education in places where PWID 
frequently congregate, such as syringe exchanges, “no-tell motels,” drug treatment centers, 
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and prisons. A few providers explicitly stated that they felt media campaigns or pamphlets 
would be less effective than word-of-mouth campaigns, and all of these providers 
emphasized the importance of peer educators delivering the information. One harm 
reduction provider stated, “You have an experience of IV [intravenous] drugs, whatever, or 
hep C…. your message is gonna be listened to. If you have somebody behind a stethoscope 
in a white blouse, or white, y’know [coat], it’s, then, it’s not gonna work.” A few harm 
reduction providers noted that their harm reduction organizations were currently educating 
PWID on PrEP, but acknowledged that their efforts needed to be ramped up further to reach 
more PWID.
Stigma.—When discussing PrEP acceptability among PWID, stigma was another 
dimension that providers felt was important to consider. Most of the harm reduction and 
PrEP providers felt that PWID may experience HIV-related stigma, noting that it could be a 
potential barrier to PrEP uptake. Most of these providers explained that taking PrEP could 
be seen as an indication of being irresponsible or unsafe and thus vulnerable to HIV 
infection. One PrEP provider said, “There’s this concept, it’s almost like their drug use isn’t 
as bad because they use a clean technique. But if you use PrEP, then maybe you’re admitting 
you’re not as careful, so then you actually have a problem.” Some PrEP providers explained 
their stigma-related concerns by stating that some of their PrEP clients who are MSM or sex 
workers experience HIV-related stigma when taking PrEP. They added that these PrEP 
clients often fear or experience stigma when their PrEP medication bottles are discovered by 
friends, partners, or family members. A couple of providers noted that PrEP education 
campaigns could be a way to reduce HIV-related stigma.
When discussing HIV-related stigma, many harm reduction and PrEP providers also 
mentioned IDU-related stigma as a barrier to PrEP uptake, often stating that IDU-related 
stigma was more serious and debilitating than HIV-related stigma. These providers often 
spoke about the pervasiveness of IDU-related stigma and how it can lead to internalized 
IDU-related stigma and/or mistreatment or discrimination in health care and law 
enforcement settings. To demonstrate the strong influence of IDU-related stigma, some PrEP 
providers explained that they suspected some of their clients hid their IDU behavior from 
them, despite admitting to risky sexual behavior. One PrEP provider explained how he found 
out that one of his clients used injection drugs:
I have one [patient] that I know injects because he was disqualified from a study 
because of the injection drug use, so I see him clinically. I knew that from behind 
the scenes, but he won’t tell me that he injects. So, I think for him, he’s fine telling 
me he has sex with men, and he’s fine telling me he wants PrEP, but he won’t tell 
me that he is injecting drugs.
Additionally, a few PrEP providers noted that HIV- and IDU-related stigma inter-sected, 
explaining that taking PrEP could be stigmatizing as it would make others suspect that the 
individual is injecting drugs.
Provider stigma was another stigma-related barrier discussed, mostly by harm reduction 
providers. Most harm reduction providers mentioned provider biases when asked about any 
relationships their harm reduction organizations had with PrEP providers, stating that it was 
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important and sometimes difficult to identify a nonstigmatizing, nonjudgmental provider for 
PWID referrals. A few of these harm reduction providers noted that stigma in the health care 
setting was not only coming from clinicians, but also from pharmacists and secretaries. 
Some harm reduction providers explained that PWID often noted the lack of stigma at 
syringe exchange sites as unique due to the poor treatment they had received in the past.
Sometimes they [syringe exchange clients] tear up because they’ve never been 
some place [a medical provider] that seems so friendly and nonstigmatizing. 
They’re like, “Wow, y’all are so nice, and how can you be so friendly to us, and 
we’re such bad people and we’re drug addicts and we’re junkies” and all this stuff. 
“Stop calling yourself those names. So what? You use drugs? Try to do it a little bit 
safer. Use a clean needle. Dispose of it properly.” And things start moving in the 
right direction.
(Harm reduction provider)
While many harm reduction providers mentioned provider stigma, only one PrEP provider 
stated that he was aware of other providers stigmatizing PWID due to a lack of 
understanding that addiction is a disease.
Drug Addiction.—Drug addiction was another barrier mentioned often by providers when 
discussing PrEP acceptability among PWID. One harm reduction provider explained how 
addiction can hinder PrEP uptake: “The thing is, theoretically, yes, they’re all for it [PrEP]
…. But when people are dope-sick, all that goes through the window.” Further, one harm 
reduction provider noted that some PWID feel that they should treat their addiction before 
going on a medication like PrEP. Some PrEP providers felt that among PWID, those who 
were already particularly engaged in protecting their own health, or “really dogged about not 
sharing needles” (PrEP provider), would be more interested in taking PrEP than other 
PWID.
PREP ADHERENCE
Many of the harm reduction and PrEP providers felt that PrEP adherence would likely be a 
major challenge for PWID. Mostly, these providers explained that adhering to a daily pill 
can be difficult for all individuals taking PrEP, but speculated that it might be especially 
difficult for PWID due to their addiction. Providers mentioned a few potential strategies to 
address poor adherence, such as medication reminders delivered by phone, Facebook, or 
email, putting up visible cues at the syringe exchange (i.e., signs), or building the habit of 
taking the PrEP pill when injecting daily. One of the PrEP providers described the first time 
he suggested to a patient who injects drugs to pair his morning injection with PrEP pill-
taking:
He [patient who injects drugs] looked at me like I had lost my mind. I just said to 
him, [Name of patient], I’m being realistic here. When you’re ready to quit, I am 
here to help. I’m going to keep encouraging you to do it. But, in the meantime, I 
can’t have you dying of HIV because then we don’t have a chance.
Providers tended to talk about PrEP adherence when asked whether they thought PWID 
would prefer oral or injectable PrEP. Oral PrEP is a daily pill, while injectable PrEP is 
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administered by a provider every 2 to 3 months. Several providers explained that they felt 
injectable PrEP would be preferred since PWID would have one less thing to worry about 
every day and would find adhering to a daily pill difficult. PrEP providers often elaborated 
that while injectable PrEP may help with daily adherence, retention in care would remain a 
significant challenge for injectable PrEP and could lead to adherence issues over time.
PREP RETENTION
Many providers, especially PrEP providers, mentioned broad retention-related challenges to 
providing PrEP to PWID. Mostly, these providers emphasized how difficult it would be for 
PWID to regularly follow up due to their inconsistent or unstable circumstances, co-
occurring diseases like mental health, and addiction. One harm reduction provider explained 
why PWID who successfully initiate PrEP may have trouble staying in care: “Sometimes 
they’re just deep into addiction where nothing really matters. Like their priorities change.” 
PrEP providers also mentioned lack of health insurance and difficulty traveling to the clinic 
as barriers to retention in care. Some providers offered potential strategies to promote 
retention in care, including incentives for coming to the clinic (i.e., transport 
reimbursements, gift cards), free services, telehealth appointments, and integrating services 
into the syringe exchange. Some providers also brought up retention issues when asked 
whether they thought PWID would prefer oral or injectable PrEP, stating that PWID would 
have difficulty with the injectable PrEP due to the need for regular visits to a provider. A few 
PrEP providers expressed serious concerns around PWID developing resistance mutations if 
clients initiated injectable PrEP and were not regimented about attending follow-up visits.
PREP ACCESSIBILITY
All providers were asked their views on three PrEP provision modalities for PWID: (1) 
syringe exchange sites providing PrEP referrals to interested PWID (i.e., Referral), (2) 
stationing a PrEP provider at a syringe exchange who provides PrEP prescriptions to 
interested PWID (i.e., Doctor prescription), and (3) syringe exchange sites providing a 
standing order for PrEP, such as a 30-day pill pack, to interested PWID (i.e., Standing 
Order) (see Tables 2 and 3).
Views on Providing PrEP Referral at a Syringe Exchange.—Many PrEP and harm 
reduction providers thought that PrEP referral at a syringe exchange would be a feasible way 
to link PWID to PrEP. When asked to select their most preferred PrEP delivery option, half 
of PrEP providers and a few harm reduction providers selected the PrEP referral option. 
Mostly, these providers felt that the PrEP delivery modality was a beneficial option since it 
was the easiest to implement and required the least amount of additional resources. One 
harm reduction provider described the effectiveness of their current referral system, saying 
that the doctor they work with trusts them to identify appropriate individuals for referral 
before checking with him, which helps to facilitate the process. One PrEP provider 
acknowledged that it may be difficult or stressful for an individual who injects drugs to 
follow up on the referral and access care but said that he felt overcoming this challenge was 
“like a stress test” and an important show of dedication to taking PrEP.
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Despite agreement among most providers that the PrEP referral option was feasible, many 
mentioned serious challenges involved with implementing the referral system. In fact, some 
PrEP providers explicitly stated that while the referral option was the most feasible to 
implement, it would probably be the least effective of all PrEP delivery options. The most 
common issues that were identified were lack of insurance coverage, PrEP-related costs, 
provider stigma, and distrust in medical providers. One harm reduction provider said, “The 
referral [is the least effective option] just because it’s an extra step. Another person that they 
[PWID] have to open up to and trust to let in their world.” Other barriers that were 
mentioned by some providers included long waiting lines at clinics/hospitals and distance 
from clinics/hospitals.
When asked for suggestions on how to improve the PrEP referral option, some providers 
recommended syringe exchanges providing “warm handoffs” to physically link the referred 
client to the provider and co-location of syringe exchange and PrEP services. Providers 
explained that these two strategies would help improve accessibility and address 
transportation barriers. Two harm reduction providers mentioned reducing the cost of PrEP 
services or subsidizing costs with financial assistance. A few PrEP providers also 
emphasized the need for syringe exchange services to play a role in increasing awareness of 
and education about PrEP to drive demand and strengthening relationships between syringe 
exchange services and PrEP delivery sites to ensure syringe exchange services know where 
to refer. One PrEP provider suggested a 24-hour hotline for PWID to call to ask questions 
about services like PrEP, as they thought PWID may be hesitant to approach syringe 
exchange services to ask questions about it.
Views on Providing Doctor Prescription at a Syringe Exchange.—Many harm 
reduction and PrEP providers felt that providing a doctor’s prescription at a syringe 
exchange was feasible. Some harm reduction providers and a few PrEP providers mentioned 
benefits of the doctor prescription option, explaining that it would make it easier to link 
PWID to doctors and ensure they get the PrEP prescription. “I think that people tend to 
value the opinions of physicians and want good medical advice. And I think that if there was 
an opportunity where something like that could happen with a doctor, it might make a 
difference” (Harm reduction provider). One harm reduction provider felt that syringe 
exchange sites would be able to carry out all of the prerequisite laboratory testing needed 
before providing a PrEP prescription.
Despite providers’ positive views on the doctor prescription option, many harm reduction 
and PrEP providers described serious barriers to implementation, mostly talking about issues 
related to offering PrEP services at syringe exchange sites. When asked about their most 
preferred PrEP delivery option, this was the least popular option across both harm reduction 
and PrEP providers. Harm reduction providers tended to focus on how incongruent PrEP 
services would be with the current way the syringe exchange operates. In particular, harm 
reduction providers explained that syringe exchange clients often like to move in and out of 
the syringe exchange quickly and that the syringe exchange site is not seen as a medical 
space, besides providing hepatitis C and HIV testing occasionally. They noted that providing 
PrEP services would be a departure from their usual protocol, as it would require time-
consuming activities, such as signing clients up for pharmaceutical companies’ patient 
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assistance programs (hereafter referred to as “patient assistance”) and/or conducting tests 
that would involve additional follow-up to get results. One harm reduction provider also 
mentioned that it would be difficult to find funds for a doctor to regularly spend time at a 
syringe exchange site. PrEP providers focused on issues around completing the required 
laboratory testing, such as HIV and kidney function testing, prior to providing the PrEP 
prescription. These PrEP providers stated that rapid HIV testing would be insufficient when 
initiating PWID on PrEP and needing to address potential cases of acute HIV infection. 
“Many people injecting drugs are doing it daily. They may not be sharing needles every day, 
but basically I imagine it would be a challenge to find people who have not been at risk for 
enough time [to start PrEP]” (PrEP provider). A couple of PrEP providers also brought up 
issues around liability and malpractice when placing medical providers in syringe exchange 
sites.
When asked about ways to improve the doctor prescription option, harm reduction and PrEP 
providers gave similar suggestions, speaking often about co-locating PrEP and harm 
reduction services and conducting mobile outreach to make it easier for PWID to access 
services and stay retained in care. One PrEP provider specified that, although mobile syringe 
exchange would be an effective way to initiate PWID on PrEP, a brick-and-mortar venue 
would be ideal for the follow-up appointments. Mostly, providers spoke about needing to be 
flexible to accommodate a hard-to-reach, transient population while still ensuring they are 
prescribing PrEP in a safe way with robust monitoring systems in place to follow up and 
retain PWID in care. A few harm reduction and PrEP providers mentioned additional 
suggestions, such as the need for more state funding, nonjudgmental treatment of PWID by 
medical providers, and getting PWID on patient assistance, potentially with the help of 
patient navigation services.
Views on Providing a Standing Order at a Syringe Exchange.—Many harm 
reduction and PrEP providers thought the standing order option was feasible; PrEP providers 
often added that they thought it would also be the most effective option. In fact, when asked 
to select their most preferred PrEP delivery option, half of harm reduction and PrEP 
providers chose standing order. Most harm reduction and PrEP providers felt that the 
standing order option would optimize accessibility by ensuring PWID didn’t have to go to a 
second location to pick up their medications or “hunt down the services” (Harm reduction 
provider). A few harm reduction providers also spoke about the ease of incorporating the 
standing order option into their current syringe exchange services, as it could be included in 
the package they give out that contains naloxone, clean syringes, and other health-related 
materials. Some PrEP providers emphasized that it would be particularly appropriate to use 
the standing order option to retain PWID in care, as opposed to initiating PWID onto PrEP, 
as there are not as many laboratory tests that need to be done during the maintenance phase.
Despite the overall positive views of the standing order option, almost all providers 
mentioned serious challenges to implementation, focusing on logistical issues around 
completing the necessary laboratory tests and follow-up monitoring appointments. PrEP 
providers often used particularly strong language, stating that they and other PrEP providers 
would feel uncomfortable distributing PrEP so easily, especially without assurance that they 
could conduct follow-up appointments and laboratory testing with PWID.
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There’s a part of me that wants to say yes, PrEP for everyone. But at the same time, 
it’s not Narcan. There are consequences. You have to have these labs [laboratory 
test results]. You have to. If you gave 3 months of PrEP in hand to an addict and 
their their HIV test came back positive, oops. That’s bad. Because they could come 
back with significant drug resistance.
(PrEP provider)
Some harm reduction providers tended to agree, saying that PrEP medication was different 
from Narcan/naloxone in that there were many requirements that need to be met before 
distributing PrEP to PWID. A few harm reduction and PrEP providers referenced the 
Centers for Disease Control and Prevention guidelines directly, noting that the standing 
order option would deviate from them.
Many providers also offered recommendations on how to improve the standing order model, 
mostly speaking about incorporating required laboratory services into syringe exchange sites 
and reducing PrEP-related costs or helping PWID get on patient assistance, acknowledging 
that these changes would require increased funding and resources to implement. One PrEP 
provider emphasized the magnitude of the structural changes needed at syringe exchange 
sites:
Interviewer: And is there anything that would be needed to make that [standing order] more 
feasible?
Interviewee: Everything is needed. You’re creating a whole new structure in a place that 
isn’t designed to provide health care. So, yes, I think we have to think about what’s the bare 
necessities that we need? I mean, you can superimpose almost anything. Like we could talk 
about hepatitis C treatment. You could do hepatitis C treatment at a needle exchange if you 
wanted to, if you built it the right way. You can do a lot of things. You could do dental care. 
It just depends upon how many layers you wanna put on top, and what’s feasible.
Harm reduction providers also often mentioned the importance of implementing PWID-
targeted PrEP education and awareness campaigns through syringe exchange activities and 
state-level support and changes in the law. One harm reduction provider preferred PrEP 
medication distribution through pharmacies to address storage and monitoring issues at 
syringe exchange sites. PrEP providers also often mentioned the importance of 
implementing robust monitoring systems to track PWID and ensure they are retained in care. 
A couple of these PrEP providers recommended using patient navigators to help get PWID 
on patient assistance and/or follow up with PWID to ensure they are adhering and planning 
to attend any follow-up appointments. One PrEP provider felt that it would be necessary to 
offer PrEP medication only to PWID who visit the syringe exchange regularly and would 
reliably come to follow-up visits.
Views on Other PrEP Provision Modalities.—All participants suggested that co-
locating harm reduction and PrEP services for “one-stop shopping” and scaling up outreach 
services to promote PrEP awareness and education would be effective strategies. Harm 
reduction providers recommended using outreach services to reach PWID at social service 
Hershow et al. Page 12













providers, specifically mentioning the Special Supplemental Nutrition Program for Women, 
Infants, and Children (WIC) program, prisons, and neighborhoods/areas where PWID 
frequent. PrEP providers recommended using mobile outreach to target PWID at established 
health or counseling services such as emergency rooms, primary care providers, Narcotics 
Anonymous/Alcoholics Anonymous, or substance use treatment centers. A few harm 
reduction providers also specified that outreach and engagement strategies should be 
informed by current or previous PWID.
Despite advocating for co-location of services and scaling up outreach, about half of the 
harm reduction and PrEP providers also mentioned serious challenges to carrying out these 
efforts. Commonly mentioned issues were lack of funds or resources, difficulty accessing 
services (even if co-located) due to low availability and transportation issues, lack of health 
insurance or patient assistance for PWID, and mistrust in the health department by PWID. 
One harm reduction provider noted the low availability of syringe exchange services across 
the state, especially in rural areas, as evidence that institutional change was necessary to 
better serve PWID: “So, it’s not so much the question of how do we reach the drug users. 
It’s the question of how do the institutions themselves need to change?”
DISCUSSION
Our findings demonstrate that most harm reduction and PrEP providers think that PrEP 
provision to PWID is acceptable and feasible, but not without complexity. Providers 
highlighted the multilevel barriers to promote PrEP acceptability, awareness, and 
accessibility due to the unique needs of PWID. Participants also discussed the urgent need to 
improve upon and build effective and appropriate PrEP provision delivery systems for PWID 
by addressing these challenges. Perceived barriers to PrEP uptake and adherence among 
PWID mentioned by providers included individual-level barriers, such as fear of stigma, risk 
compensation, low PrEP awareness, drug addiction, and lack of health insurance; 
community-level barriers, including HIV- and IDU-related stigma; and health systems–level 
barriers, including provider stigma, low availability and lack of integration of harm 
reduction and PrEP services, high cost of PrEP medication, and lack of PrEP awareness 
strategies. Despite these numerous barriers, providers agreed that PrEP provision for PWID 
was feasible if resources and funds were available to improve and implement thoughtful 
solutions, such as co-location of harm reduction and PrEP services and scaled-up outreach 
services.
Our results highlighted that few harm reduction or PrEP providers had formal relationships 
with each other, although all agreed that building strong partnerships would improve their 
ability to engage and serve PWID. PrEP providers tended to explain that they didn’t have 
enough time or resources to formalize these relationships, while harm reduction providers 
noted that they were unsure how to identify appropriate PrEP providers whom they could 
trust to be nonstigmatizing towards PWID that they referred. Research shows that PWID 
have high levels of trust in needle and syringe programs (Treloar, Rance, Yates, & Mao, 
2016) and that needle exchange services should be one component of a comprehensive HIV 
prevention package (Birkhead et al., 2007; Strike & Miskovic, 2018), suggesting that both 
harm reduction and primary care providers could benefit greatly from building these 
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relationships. Further, although PrEP and harm reduction providers had limited interaction 
with each other, the fact that they tended to agree on PrEP-related barriers and effective 
strategies for engaging PWID in PrEP care indicates that partnerships could be feasible as 
well as fruitful. Our findings suggest that systems are needed to connect harm reduction and 
PrEP providers. Additionally, stigma reduction interventions for PrEP providers are needed 
to ensure better care for PWID and stronger relationships between harm reduction and PrEP 
providers.
Despite agreement on views regarding PrEP-related barriers and PrEP provision modalities 
for PWID, several structural differences between harm reduction and PrEP providers were 
identified. For one, harm reduction providers often noted that syringe exchange services 
operate in a fundamentally different way than PrEP services. Syringe exchange services are 
designed to be nonmedical spaces and to accommodate clients quickly, while PrEP services 
involve one-on-one consultation and laboratory tests. While co-locating services was highly 
recommended by both harm reduction and PrEP providers, results suggest that bridging the 
cultural norms and practical necessities involved in integrating these services will need to be 
considered. In Vancouver, a health facility has been able to successfully implement an 
integrated, multidisciplinary model to address psychiatric, addiction-related, social, and 
medical needs for PWID (Birkhead et al., 2007). This model has effectively enhanced access 
to HCV treatment (Alimohammadi, Holeksa, Thiam, Truong, & Conway, 2018) and 
optimized the benefits of antiretroviral treatment (ART) among HIV-positive PWID (Ti et 
al., 2017). However, issues around stigma (Collins et al., 2016) were observed and social 
improvements among PWID were limited (Bozinoff, Small, Long, DeBeck, & Fast, 2017). 
Evidence from the Vancouver model highlights the effectiveness of using an integrated 
approach and the importance of being thoughtful about the complex needs of PWID when 
operationalizing it.
Harm reduction and PrEP providers expressed fairly similar views on and preferences for the 
three PrEP provision modalities: providing PrEP referrals at syringe exchange sites, 
stationing a PrEP provider at a syringe exchange site to provide PrEP prescriptions, and 
providing a standing order for PrEP at syringe exchange sites. Many providers thought all 
three PrEP provision modalities for PWID were feasible; PrEP providers most often selected 
the referral and standing order options as their most preferred PrEP provision modalities, 
while harm reduction providers most often selected the standing order option.
Although many providers endorsed the same PrEP provision modalities, harm reduction and 
PrEP providers tended to differ on preferred requirements for PWID when discussing PrEP 
uptake, adherence, and retention. Harm reduction providers often emphasized the 
importance of being flexible by reaching PWID through mobile outreach or continuing to 
treat PWID if they miss a follow-up appointment. PrEP providers often spoke about their 
discomfort initially prescribing PrEP without certain laboratory test results or assurance of 
seeing clients at follow-up appointments. Further, PrEP providers often suggested that there 
should be separate models in place for PrEP initiation and for PrEP adherence due to the 
increased requirements for PrEP initiation. To facilitate initiation, rapid entry programs 
implemented in the Southern U.S. have effectively improved time to ART initiation and time 
to viral suppression among people living with HIV (Colasanti et al., 2018), suggesting that a 
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similar approach that eliminates select laboratory data and administrative requirements may 
be optimal for promoting PrEP among PWID. However, our findings demonstrate that PrEP 
providers may be resistant to such an approach for PrEP without sufficient evidence of 
effectiveness.
LIMITATIONS
This study has several limitations. The sample size is small; however, qualitative research is 
intended to explore participants’ views on selected topics, as opposed to assessing the 
prevalence of attitudes, beliefs, or health outcomes in a sample. Thus, the sample size is 
sufficient considering the study objectives (Guest, Bunce, & Johnson, 2006), although 
findings should not be generalized beyond harm reduction and PrEP providers in the Triad 
and Triangle region of NC. Additionally, participants who were recruited using snowball 
sampling may have held views similar to those of the providers who had connected them to 
the study, making the range of perspectives among participants less diverse. Further, 
participants were asked to assess the feasibility of PrEP provision models for PWID, most of 
which are not currently in place in NC. As a result, the responses expressed here are based 
on their understanding of PrEP and HIV prevention care and policies, rather than direct 
experiences working on these PrEP provision delivery systems for PWID. Finally, the 
perspectives of PWID on PrEP provision models are not presented, limiting our 
understanding of acceptability.
CONCLUSIONS
In summary, the results of this study suggest that providing PrEP to PWID in harm reduction 
sites is potentially feasible but is likely to require substantial resources and efforts to 
overcome existing barriers and effectively reach and engage PWID with PrEP in NC. The 
providers participating in this study felt that co-location of syringe exchange and PrEP 
services and scaled-up outreach services would be the most effective approaches to 
providing PrEP to PWID but would require major changes to the current infrastructure of the 
health system that serves PWID. Integrated models, such as the Vancouver model, 
implemented in other settings can be used to inform development of PrEP uptake and 
adherence interventions for PWID.
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TABLE 1.
Interview Guide Topics and Example Questions
Topic Example question
PrEP prescription
a How do you determine which people who inject drugs to prescribe PrEP to?
PrEP referral
b Whom do you currently refer for PrEP?
Relationship between PrEP 
and harm reduction 
providers
Whom do you currently work with in harm reduction? Would you like to do more with them? What would help 
you make those relationships more robust?
Perceived PrEP benefits Do you think injection drug users would benefit from PrEP? Why/why not?
PrEP acceptability Do you think people who inject drugs would be interested in taking PrEP to prevent HIV? Why/why not?
Views on PrEP provision 
modalities
Please let us know if you think the following would be feasible and why or why not: (a) Referring injection 
drug users to a PrEP clinic during syringe exchange; (b) Having a doctor prescribe PrEP during syringe 
exchange outreach sessions; (c) Making PrEP available via “standing order,” similar to naloxone, and providing 
people with PrEP pill packs during syringe exchange.
a
Questions on this topic were for PrEP providers only;
b
Questions on this topic were for harm reduction providers only.
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TABLE 2.
Views on Feasibility
PrEP providers (n = 10) Harm reduction providers (n = 10)
Referral
 Feasible 8 6
 Not feasible 1 1
 Unsure/Unclear 1 3
Doctor prescription
 Feasible 8 7
 Not feasible 0 3
 Unsure/Unclear 2 0
Standing order
 Feasible 6 9
 Not feasible 3 1
 Unsure/Unclear 1 0
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TABLE 3.
Most Preferred PrEP Provision Modality
Modality PrEP providers (n = 10)
a Harm reduction (n = 10)
Referral 5 2
Doctor prescription 1 3
Standing order 5 5
Not asked/answered 3 1
Note. Since some providers selected two out of the three options as the PrEP provision modality they prefer the most, the numbers sum to more 
than 10 for PrEP and Harm reduction providers.
a
Three providers selected referral as their preferred provision modality in terms of feasibility and standing order as their preferred provision 
modality in terms of effectiveness in increasing PrEP uptake; one provider selected referral as his preferred provision modality in terms of 
feasibility and doctor prescription as his preferred provision modality in terms of effectiveness and safety.
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